LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
04/29/2022 - 08:02 AM
LONDON April 29, 2022
A replay of the webcast will be available on the Investor's section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.
About LumiraDx LumiraDx (Nasdaq: LMDX ) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
LumiraDx is based in the UK with more than 1600 employees worldwide. Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com
Contact: Colleen McMillen Colleen.McMillen@lumiradx.com
https://www.prnewswire.com/news-releases/lumiradx-to-announce-first-quarter-financial-results-and-host-quarterly-conference-call-on-may-11-301536039.html
SOURCE LumiraDx
LMDX Rankings
#5440 Ranked by Stock Gains
LMDX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About LMDX
healthcare organizations continue to wrestle with avoidable costs, preventable errors, and operational inefficiency, all while aspiring to improve their consumer experience, outcomes, and bottom line. meanwhile our economies continue to be challenged by rising healthcare costs attributable to fragmented care and long term conditions, especially diabetes, heart failure, copd, and their co-morbidities. common approaches to address these challenges – rip-and-replace information systems, deploy siloed programs that hope to “manage” high-risk patients, use minimally interconnected systems to coordinate care – have proven exorbitantly expensive, unduly cumbersome, financially unsustainable, and eventually inadequate to achieve desired benefits. lumiradx offers proven solutions to directly address these challenges, and partners with its clients to help achieve better health care, social care, and financial outcomes, an improved consumer experience, and the agility to continue this transformat
